Clinical leadership F2G is a clinical-stage biopharma pursuing a novel antifungal class (oritomides) with olorofim as lead candidate and an ongoing global Phase 3 trial (OASIS) against invasive fungal diseases, signaling a potential near-term demand for advanced antifungal options.

Oral and IV potential The olorofim program targets a distinct DHODH mechanism, with fungicidal activity across resistant mould infections, suggesting opportunities to collaborate with specialty hospitals, infectious disease networks, and global payers seeking innovative therapies for difficult-to-treat aspergillosis and similar infections.

Regulatory momentum Orphan drug status in the EU, FDA QIDP designation, and Breakthrough Therapy designation create potential regulatory and market access accelerators, enabling faster path to launch and favorable reimbursement discussions in multiple regions.

Strategic footprint Headquartered in the UK with US and Austria subsidiaries positions F2G for cross-continental access to clinical sites, talent, and regional partnerships, offering multiple entry points for co-development, licensing, or distribution agreements.

Financial readiness With substantial funding and revenue signals in the mid-market range, F2G’s strong balance sheet supports continued clinical development, strategic partnerships, and potential in-licensing discussions to scale manufacturing and commercialization capabilities.